QMatter, a quantum technology startup, has raised £900,000 in a pre-seed round led by 55 North, with participation from XTX Ventures, Bellstate Oy and the Conception X Angel Syndicate. It develops quantum compression technology that reduces the size of complex computational problems before they are processed on quantum or classical systems. The funding will be used to further develop and scale its quantum compression platform.
Simulating quantum mechanics is computationally demanding, and current classical and quantum computers cannot handle the most complex challenges in drug discovery and materials science. QMatter applies principles from quantum mechanics to compress problems to their essential core, enabling them to be processed on today’s hardware. This approach extends the capability of both near-term and future quantum computers, while also accelerating classical algorithms across systems ranging from consumer hardware to supercomputers.
The startup is focused on the life sciences market, working with pharmaceutical and biotechnology companies to accelerate research and development by enabling improved simulation data. In parallel, it is generating physics-informed data libraries to support machine learning companies in training models using problem-specific data.
QMatter was founded in 2024 by Dr. Alexis Ralli and Dr. Timothy Weaving, alongside Prof. Peter Coveney and Prof. Peter Love. The founding team has backgrounds in quantum computing and high-performance computing, with a focus on life science applications.
QMatter compresses complex quantum problems to their essential core, ensuring solutions remain both accurate and useful. By doing so, we unlock greater performance from today's quantum hardware while broadening the problem landscape for future error-corrected machines.
Quantum computing promises to be transformational for the hardest problems we face, but the full value remains unrealized due to real-world limitations that constrain the size of problems we can address today. This investment will support the continued development of our quantum compression platform.
The first commercially valuable applications of quantum computing devices will likely be in chemistry and pharmaceuticals. QMatter’s compression approach accelerates the timelines and brings these applications closer to the market.
